Selected Publications
Haddad TC, Suman VJ, D’ Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Young SO, Clark AS, Ingrid AM, Keyomarsi K, Hobday TJ, Peethambaram PP, O’Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP.: Phase II Trial of Alisertib Alone or Combined with Fulvestrant in Endocrine-resistant, Advanced Breast Cancer (TBCRC 041) JAMA Oncology : 2022.
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen, YY Balassanian R, Nanda R, Parker B A Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, van't Veer L, Symmans WF, Esserman L, Pusztai L: Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials Ann Oncol. 22 : S0923-7534,2022.
Mankoff D, Clark AS, Edmonds CE, O'Brien SR, Pantel A: 16α-[18F]fluoro-17β-estradiol positron emission tomography (FES-PET) to Measure Regional Estrogen Receptor (ER) Expression in Breast Cancer
Journal of Clinical Oncology : 2022.
Martei YM, Clark AS: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor-Positive, ERBB2-Negative Breast Cancer Treatment JAMA Netw Open.
5 (4): 2022.
Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Schulman LN, Mamtani R, Hubbard RA.: Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States J Natl Cancer Inst. 114 (4): 571-578,2022.
Verbus EA, Rossi AJ, Clark AS, Taunk NK, Nayak A, Hernandez JM, Tchou JC.: Preoperative Use of a Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer Ann Surg Oncol. 29 (3): 1530-1532,2022.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Jelle Wesseling, Martín M, Monte-Millán MD, López-Tarruella S, I-SPY 2 Trial Consortium; Boughey J.C, Goetz M.P, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Mi-Ok K, van 't Veer LG, Esserman LJ, Symmans WF: Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicenter pooled analysis of 5161 patients Lancet Oncol
23 (1): 149-160,2022.
Makhlin I, McAndrew NP, Wileyto P, Clark AS, Holmes R, Bottalico LN, Mesaros C, Blair I, Jeschke G, Fox KR, Domchek SM, Matro JM, Bradbury AR, Feldman M, Hexner EO, Bromberg JF, DeMichele A: A Phase II Trial of the JAK-Inhibitor Ruxolitinib with Exemestane for Estrogen Receptor Positive, Aromatase Inhibitor Resistant, Advanced Breast Cancer NPJ Breast : 2022.
Ulaner GA, Fowler AM, Clark AS, Linden H.: Estrogen Receptor (ER)-targeted imaging with 18F-Fluoroestradiol (18F-FES): Clinical Impact Radiology : 2022.
Thomas A, Clark AS, Yau C, Wolf DM, van 't Veer L, Douglas EH, Chien AJ, Huppert LA, Rugo HS, Shatsky RA, Isaacs C, Berry DA, Yee D, DeMichele A, Esserman L, I-SPY2 Consortium: Molecular Subtype Predicts Pathologic Complete Response in HER2-positive Breast Cancer in the I-SPY2 Trial
J Clin Oncol 40 : 2022.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia,
PA
19104
Phone: 215-662-7096
Patient appointments: 800-789-7366